UNITED STATES |
September 26, 2003 |
Date of report (Date of earliest event reported) |
GENELABS TECHNOLOGIES, INC. |
(Exact Name of Registrant as Specified in Charter) |
California |
(State or Other Jurisdiction of Incorporation) |
0-19222 | 94-3010150 | |
(Commission File Number) | (IRS Employer Identification No.) |
505 Penobscot Drive Redwood City, California | 94063 | |
(Address of Principal Executive Offices) | (Zip Code) |
(650) 369-9500 |
(Registrant's telephone number, including area code) |
Item 5. Other Events and Required FD Disclosure. |
On September 26, 2003, Genelabs Technologies, Inc. issued a press release providing an update on the development of its investigational drug for systemic lupus erythematosus. |
Item 7. Financial Statements,Pro Forma Financial Information and Exhibits. |
EXHIBIT NO. | DESCRIPTION | ||
99.1 | Press Release dated September 26, 2003. |
SIGNATURE |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. |
Dated: September 26, 2003 |
GENELABS TECHNOLOGIES, INC. |
By: | /s/ James A.D. Smith | |||
Name: | James A. D. Smith | |
Title: | President |
EXHIBIT INDEX |
EXHIBIT NO. | DESCRIPTION | ||
99.1 | Press Release dated September 26, 2003. |